Top News

Genkyotex's NOX1&4 Inhibitor Strategy in Liver Fibrosis Supported by New Preclinical Results

Business Wire, 30.07.2015

Genkyotex, the leading developer of selective NOX inhibitors, announced today publication of results from two independent studies confirming the important role played by both NOX1 and NOX4 enzymes in the development of liver fibrosis. This research, conducted at University of California, San Diego, and University of California, Davis, supports the use of dual NOX1&4 inhibitors for the treatment of liver fibrosis, such as nonalcoholic steatohepatitis (NASH). Genkyotex's lead inhibitor, GKT137831, is in a Ph2 trial in diabetic nephropathy, the data from which is also being analyzed to support the company's plan to evaluate the drug in a range of fibrotic diseases.

more

Next Event

 

Community Login







Bachem Holding AG

loroch.ch